Pharmaceutical companies are heading toward a steep patent cliff that could strip more than $230 billion in US drug sales ...

Keytruda (pembrolizumab) is approved for head and neck squamous cell carcinoma as a perioperative treatment regimen.

The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with the U.S., trailing only China.

Keytruda (pembrolizumab) is a prescription drug used to treat certain types of cancer in adults and some children. Keytruda isn’t known to interact with alcohol, other medications, or ...

Merck unveiled encouraging Phase 3 KEYNOTE-689 trial results for KEYTRUDA at the AACR 2025 Meeting, sparking investor enthusiasm. The results helped boost Merck’s stock price by 6% in just a week, ...

Key Takeaways Evorpacept and Keytruda combination failed to meet primary endpoints in ASPEN-03 and ASPEN-04 trials for advanced HNSCC. The combination did not improve objective response rates compared ...

Management highlighted plans to reduce inventory through a temporary shipment pause. Tariff implementations, particularly between the U.S. and China, could result in $200 million in additional costs.

Previously, in a phase 1/1b trial, ficerafusp alfa paired with Keytruda demonstrated a 64% overall response rate, an 18% complete response rate and median progression free survival of 9.8 months ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption ...

Your Keytruda treatment may last for around 2 years, but certain factors may mean that you’ll receive the drug for a longer or shorter time. If you have questions about what to expect from your ...

NEW YORK, NY, USA & TOKYO, Japan I February 10, 2025 I Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced additional follow-up ...

J Clin Oncol 43, 2025 (suppl 5; abstr 664) Powels T, Valderrama BP, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med 2024;390:875-888. PADCEV ...